ic9-car.b7-h3 t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 27, 2024 (NCT06347068)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06305299 | Phase 1 | Jul 29, 2024 | University of North Carolina at Chapel Hill |
| NCT06347068 | Phase 1 | Jun 27, 2024 | Bellicum Pharmaceuticals, University of North Carolina at Chapel Hill |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1